{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NOX.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NOX.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NOX.AU\",,,,,undefined,":{"symbol":"NOX.AU","market":"AU","secType":"STK","nameCN":"NOXOPHARM LTD","latestPrice":0.078,"timestamp":1741148053540,"preClose":0.081,"halted":0,"volume":336033,"delay":0,"changeRate":-0.037037,"change":-0.003,"floatShares":195506720,"shares":292237950,"eps":-0.00792,"lyrEps":-0.012243,"pbRate":5.27,"amount":27059,"amplitude":0.049383,"volumeRatio":3.51959,"dividePrice":0,"prevYearClose":0.093,"fiveDayClose":0.084,"twentyDayClose":0.095},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NOX.AU\",,,,,undefined,":{"symbol":"NOX.AU","floatShares":195506720,"roa":"-45.58%","roe":"-42.50%","lyrEps":-0.012243,"volumeRatio":3.51959,"shares":292237950,"dividePrice":0,"high":0.082,"amplitude":0.049383,"preClose":0.081,"low":0.078,"week52Low":0.058,"pbRate":"5.27","psRate":"9.72","week52High":0.15,"institutionHeld":0,"latestPrice":0.078,"committee":0.99956,"eps":-0.00792,"divideRate":0,"volume":336033,"delay":0,"ttmEps":-0.00792,"open":0.082,"prevYearClose":0.093,"prevWeekClose":0.081,"prevMonthClose":0.081,"prevQuarterClose":0.093,"fiveDayClose":0.084,"twentyDayClose":0.095,"sixtyDayClose":0.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NOX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NOX.AU\",market:\"AU\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NOX.AU\",params:#limit:6,delay:false,,,undefined,":[{"market":"AU","name":"Novel Coronavirus Treatment","bkCode":"BK7501","id":"package_au_concept_xgzlg","changeRate":-0.010065},{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.003985}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NOX.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2509275453","title":"BUZZ-Australia's Nyrada rises on nod to start brain injury drug's clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2509275453","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509275453?lang=en_us&edition=fundamental","pubTime":"2025-02-07 11:42","pubTimestamp":1738899746,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Nyrada rises on nod to start brain injury drug's clinical trial** Nyrada NYR.AX soars 9.2% to A$0.083, highest since Jan. 23; set for biggest intraday pct gain since Dec. 16, 2024** B","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nL4N3OY0A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NYR.AU","BK7067","BK7501","NOX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2508910283","title":"BUZZ-Australia's Noxopharm surges on drug passing safety tests","url":"https://stock-news.laohu8.com/highlight/detail?id=2508910283","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508910283?lang=en_us&edition=fundamental","pubTime":"2025-02-04 11:46","pubTimestamp":1738640777,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Noxopharm surges on drug passing safety tests** Noxopharm NOX.AX soars 12.9% to A$0.096, snapping three sessions of declines** Stock set for biggest intraday pct gain since Nov. 15, 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nL4N3OV08R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","NOX.AU","BK7067"],"gpt_icon":0},{"id":"2508317406","title":"ASX Small-Cap Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2508317406","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508317406?lang=en_us&edition=fundamental","pubTime":"2025-02-04 07:42","pubTimestamp":1738626140,"startTime":"0","endTime":"0","summary":"Investors are likely to keep an eye on the following small-cap stocks listed on the Australian Securities Exchange.Noxopharm Noxopharm passed preclinical safety tests for its SOF-SKN lupus drug candidate, part of drug development before a phase one clinical trial. The drug candidate's active ingredient passed both in vitro genotoxicity studies and the cardiac safety test without any safety issues identified.New Frontier Minerals New Frontier Minerals completed a high-resolution, helicopter-borne radiometric and magnetic survey at the Harts Range project in the Northern Territory. The geophysical survey data is being processed and interpreted, with preliminary findings expected soon.Corazon Mining Corazon Mining completed an aerial versatile time domain electromagnetic geophysical survey at the MacBride project in Canada. The survey identified numerous conductors, which the company plans to use to define priority drill targets for the first phase of drilling, scheduled in the first quar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NFM.AU","BSN.AU","BK7110","AHN.AU","CZN.AU","NOX.AU","BK7095","BK7083","BK7501","BK7067","BK7508"],"gpt_icon":0},{"id":"2508810400","title":"Noxopharm jumps as flagship lupus drug clears first-pass in vitro safety tests","url":"https://stock-news.laohu8.com/highlight/detail?id=2508810400","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508810400?lang=en_us&edition=fundamental","pubTime":"2025-02-04 07:30","pubTimestamp":1738625400,"startTime":"0","endTime":"0","summary":"Noxopharm  has reported its lupus medication in development, SOF-SKN, has passed first-stage in vitro safety tests before clinical trials.The stock jumped 11% out the gate, to 10cps, on thin trades on Tuesday.Lupus is an autoimmune condition that turns the body’s defences against it, ultimately culminating in organ and tissue damage.Noxopoharm’s SOF-SKN is a topical treatment targeting specific receptors in the body, particularly a receptor called TLR7 which is believed to be associated with the autoimmune condition. SOF-SKN is a topical gel and is described as a Sofra drug candidate.In vitro tests have now shown, in line with international standards, that the drug is unlikely to cause genetic mutations or cardiac toxicity. In vitro tests effectively work on tissue samples in Petri dishes or similar environments.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/noxopharm-jumps-as-flagship-lupus-drug-clears-first-pass-in-vitro-safety-tests-2025-02-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7501","BK7508","NOX.AU","BK7067"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":12}]}}